|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MIR205HG |
Gene summary for MIR205HG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MIR205HG | Gene ID | 642587 |
| Gene name | MIR205 host gene | |
| Gene Alias | LINC00510 | |
| Cytomap | 1q32.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 642587 | MIR205HG | LZE22D1 | Human | Esophagus | HGIN | 6.26e-13 | 2.21e+00 | 0.0595 |
| 642587 | MIR205HG | LZE22T | Human | Esophagus | ESCC | 3.86e-07 | 2.80e+00 | 0.068 |
| 642587 | MIR205HG | LZE24T | Human | Esophagus | ESCC | 2.49e-18 | 2.48e+00 | 0.0596 |
| 642587 | MIR205HG | LZE22D3 | Human | Esophagus | HGIN | 2.69e-27 | 2.75e+00 | 0.0653 |
| 642587 | MIR205HG | LZE21T | Human | Esophagus | ESCC | 2.00e-11 | 2.03e+00 | 0.0655 |
| 642587 | MIR205HG | P1T-E | Human | Esophagus | ESCC | 1.79e-13 | -1.21e+00 | 0.0875 |
| 642587 | MIR205HG | P2T-E | Human | Esophagus | ESCC | 1.72e-54 | -1.21e+00 | 0.1177 |
| 642587 | MIR205HG | P4T-E | Human | Esophagus | ESCC | 3.13e-36 | -1.21e+00 | 0.1323 |
| 642587 | MIR205HG | P5T-E | Human | Esophagus | ESCC | 6.31e-57 | -1.21e+00 | 0.1327 |
| 642587 | MIR205HG | P8T-E | Human | Esophagus | ESCC | 1.96e-56 | -1.21e+00 | 0.0889 |
| 642587 | MIR205HG | P9T-E | Human | Esophagus | ESCC | 2.21e-36 | -1.21e+00 | 0.1131 |
| 642587 | MIR205HG | P10T-E | Human | Esophagus | ESCC | 6.31e-57 | -1.21e+00 | 0.116 |
| 642587 | MIR205HG | P11T-E | Human | Esophagus | ESCC | 2.71e-17 | -1.21e+00 | 0.1426 |
| 642587 | MIR205HG | P12T-E | Human | Esophagus | ESCC | 1.96e-56 | -1.21e+00 | 0.1122 |
| 642587 | MIR205HG | P15T-E | Human | Esophagus | ESCC | 5.09e-41 | -1.21e+00 | 0.1149 |
| 642587 | MIR205HG | P16T-E | Human | Esophagus | ESCC | 1.96e-56 | -1.21e+00 | 0.1153 |
| 642587 | MIR205HG | P17T-E | Human | Esophagus | ESCC | 4.78e-16 | -1.21e+00 | 0.1278 |
| 642587 | MIR205HG | P19T-E | Human | Esophagus | ESCC | 9.48e-07 | -1.21e+00 | 0.1662 |
| 642587 | MIR205HG | P20T-E | Human | Esophagus | ESCC | 2.62e-38 | -1.21e+00 | 0.1124 |
| 642587 | MIR205HG | P21T-E | Human | Esophagus | ESCC | 5.65e-55 | -1.21e+00 | 0.1617 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |